This is the authors' abstract. We don't add key points for this paper.
HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lane et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: